2026年11月4日星期三
M
Panorama Universal
Noticias globales
NTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaWhy PC makers are turning back to China— 日经 Nikkei AsiaIndonesia chief of staff sacked for allegedly wiretapping President Prabowo— 日经 Nikkei AsiaNTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaWhy PC makers are turning back to China— 日经 Nikkei AsiaIndonesia chief of staff sacked for allegedly wiretapping President Prabowo— 日经 Nikkei Asia

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial

Fuente Nature 生命科学Hace 1 días
Resumen del contenido

Este sitio solo proporciona títulos e índices de resúmenes; el contenido completo y los derechos de autor pertenecen al publicador original. Haga clic en el enlace original para leerlo.

Ir al texto original
Canal al que pertenece
Ciencia
Región a la que pertenece
Perspectiva global
Idioma original
English
Número de entrada
science-f81c0280

Comments 0 comments

No comments yet. Be the first.

Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial · Panorama Universal